How much did La Jolla Pharmaceutical achieve in EBIT for the current year?
In the current year, La Jolla Pharmaceutical has achieved an EBIT of 18.25 M USD.
La Jolla Pharmaceutical EBIT 2024
La Jolla Pharmaceutical EBIT
18.25 M USD
Ticker
LJPC
ISIN
US5034596040
WKN
A1XB6B
In 2024, La Jolla Pharmaceutical's EBIT was 18.25 M USD, a 104.38% increase from the 8.93 M USD EBIT recorded in the previous year.
The La Jolla Pharmaceutical EBIT history
| YEAR | EBIT (undefined USD) |
|---|---|
| 2026e | 77.6 |
| 2025e | 44.5 |
| 2024e | 18.25 |
| 2023e | 8.93 |
| 2022e | 2.28 |
| 2021 | 21.83 |
| 2020 | -35.84 |
| 2019 | -109.8 |
| 2018 | -194.05 |
| 2017 | -115.43 |
| 2016 | -78.37 |
| 2015 | -41.97 |
| 2014 | -21.34 |
| 2013 | -17.94 |
| 2012 | -10.74 |
| 2011 | -2.27 |
| 2010 | -3.93 |
| 2009 | -8.64 |
| 2008 | -60.73 |
| 2007 | -55.69 |
| 2006 | -42.13 |
| 2005 | -28 |
| 2004 | -40.74 |
| 2003 | -39.29 |
| 2002 | -44.64 |
La Jolla Pharmaceutical Revenue, EBIT, Net Income US5034596040 · A1XB6B
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into La Jolla Pharmaceutical, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by La Jolla Pharmaceutical from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects La Jolla Pharmaceutical’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of La Jolla Pharmaceutical. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into La Jolla Pharmaceutical’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing La Jolla Pharmaceutical’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on La Jolla Pharmaceutical’s growth potential.
La Jolla Pharmaceutical Revenue, EBIT and net profit per share
| Date | La Jolla Pharmaceutical Revenue | La Jolla Pharmaceutical EBIT | La Jolla Pharmaceutical Net Income |
|---|---|---|---|
| 2026e | 93.75 M undefined | 77.6 M undefined | 75.07 M undefined |
| 2025e | 87.23 M undefined | 44.5 M undefined | 30.03 M undefined |
| 2024e | 77.41 M undefined | 18.25 M undefined | 12.25 M undefined |
| 2023e | 65.23 M undefined | 8.93 M undefined | 6 M undefined |
| 2022e | 53.84 M undefined | 2.28 M undefined | 1.04 M undefined |
| 2021 | 75.72 M undefined | 21.83 M undefined | 19.66 M undefined |
| 2020 | 33.42 M undefined | -35.84 M undefined | -39.42 M undefined |
| 2019 | 23.05 M undefined | -109.8 M undefined | -116.51 M undefined |
| 2018 | 10.06 M undefined | -194.05 M undefined | -199.47 M undefined |
| 2017 | 0 undefined | -115.43 M undefined | -114.8 M undefined |
| 2016 | 620,000 undefined | -78.37 M undefined | -78.19 M undefined |
| 2015 | 1.06 M undefined | -41.97 M undefined | -41.91 M undefined |
| 2014 | 0 undefined | -21.34 M undefined | -21.31 M undefined |
| 2013 | 0 undefined | -17.94 M undefined | -18.74 M undefined |
| 2012 | 0 undefined | -10.74 M undefined | -8.52 M undefined |
| 2011 | 0 undefined | -2.27 M undefined | -11.67 M undefined |
| 2010 | 0 undefined | -3.93 M undefined | -4.23 M undefined |
| 2009 | 8.13 M undefined | -8.64 M undefined | -8.63 M undefined |
| 2008 | 0 undefined | -60.73 M undefined | -62.85 M undefined |
| 2007 | 0 undefined | -55.69 M undefined | -53.08 M undefined |
| 2006 | 0 undefined | -42.13 M undefined | -39.45 M undefined |
| 2005 | 0 undefined | -28 M undefined | -27.36 M undefined |
| 2004 | 0 undefined | -40.74 M undefined | -40.54 M undefined |
| 2003 | 0 undefined | -39.29 M undefined | -38.84 M undefined |
| 2002 | 0 undefined | -44.64 M undefined | -43.32 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2002 | 0 USD | -44.64 M USD | -43.32 M USD |
| 2003 | 0 USD | -39.29 M USD | -38.84 M USD |
| 2004 | 0 USD | -40.74 M USD | -40.54 M USD |
| 2005 | 0 USD | -28 M USD | -27.36 M USD |
| 2006 | 0 USD | -42.13 M USD | -39.45 M USD |
| 2007 | 0 USD | -55.69 M USD | -53.08 M USD |
| 2008 | 0 USD | -60.73 M USD | -62.85 M USD |
| 2009 | 8.13 M USD | -8.64 M USD | -8.63 M USD |
| 2010 | 0 USD | -3.93 M USD | -4.23 M USD |
| 2011 | 0 USD | -2.27 M USD | -11.67 M USD |
| 2012 | 0 USD | -10.74 M USD | -8.52 M USD |
| 2013 | 0 USD | -17.94 M USD | -18.74 M USD |
| 2014 | 0 USD | -21.34 M USD | -21.31 M USD |
| 2015 | 1.06 M USD | -41.97 M USD | -41.91 M USD |
| 2016 | 620,000 USD | -78.37 M USD | -78.19 M USD |
| 2017 | 0 USD | -115.43 M USD | -114.8 M USD |
| 2018 | 10.06 M USD | -194.05 M USD | -199.47 M USD |
| 2019 | 23.05 M USD | -109.8 M USD | -116.51 M USD |
| 2020 | 33.42 M USD | -35.84 M USD | -39.42 M USD |
| 2021 | 75.72 M USD | 21.83 M USD | 19.66 M USD |
| 2022e | 53.84 M USD | 2.28 M USD | 1.04 M USD |
| 2023e | 65.23 M USD | 8.93 M USD | 6 M USD |
| 2024e | 77.41 M USD | 18.25 M USD | 12.25 M USD |
| 2025e | 87.23 M USD | 44.5 M USD | 30.03 M USD |
| 2026e | 93.75 M USD | 77.6 M USD | 75.07 M USD |
La Jolla Pharmaceutical stock margins US5034596040 · A1XB6B
The La Jolla Pharmaceutical margin analysis displays the gross margin, EBIT margin, as well as the profit margin of La Jolla Pharmaceutical. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for La Jolla Pharmaceutical.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the La Jolla Pharmaceutical's sales revenue. A higher gross margin percentage indicates that the La Jolla Pharmaceutical retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the La Jolla Pharmaceutical's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the La Jolla Pharmaceutical's total revenue generated. When comparing the revenue margin year over year, investors can gauge the La Jolla Pharmaceutical's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the La Jolla Pharmaceutical. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the La Jolla Pharmaceutical's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
La Jolla Pharmaceutical Margin History
| La Jolla Pharmaceutical Gross margin | La Jolla Pharmaceutical Profit margin | La Jolla Pharmaceutical EBIT margin | La Jolla Pharmaceutical Profit margin |
|---|---|---|---|
| 2026e | 82.19 % | 82.78 % | 80.08 % |
| 2025e | 82.19 % | 51.01 % | 34.42 % |
| 2024e | 82.19 % | 23.57 % | 15.83 % |
| 2023e | 82.19 % | 13.69 % | 9.19 % |
| 2022e | 82.19 % | 4.23 % | 1.94 % |
| 2021 | 82.19 % | 28.83 % | 25.96 % |
| 2020 | 76.6 % | -107.24 % | -117.95 % |
| 2019 | 89.63 % | -476.36 % | -505.47 % |
| 2018 | 83.6 % | -1,928.93 % | -1,982.8 % |
| 2017 | 82.19 % | 0 % | 0 % |
| 2016 | 82.19 % | -12,640.32 % | -12,611.29 % |
| 2015 | 82.19 % | -3,959.43 % | -3,953.77 % |
| 2014 | 82.19 % | 0 % | 0 % |
| 2013 | 82.19 % | 0 % | 0 % |
| 2012 | 82.19 % | 0 % | 0 % |
| 2011 | 82.19 % | 0 % | 0 % |
| 2010 | 82.19 % | 0 % | 0 % |
| 2009 | 82.19 % | -106.27 % | -106.15 % |
| 2008 | 82.19 % | 0 % | 0 % |
| 2007 | 82.19 % | 0 % | 0 % |
| 2006 | 82.19 % | 0 % | 0 % |
| 2005 | 82.19 % | 0 % | 0 % |
| 2004 | 82.19 % | 0 % | 0 % |
| 2003 | 82.19 % | 0 % | 0 % |
| 2002 | 82.19 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2002 | 82.19 % | 0 % | 0 % |
| 2003 | 82.19 % | 0 % | 0 % |
| 2004 | 82.19 % | 0 % | 0 % |
| 2005 | 82.19 % | 0 % | 0 % |
| 2006 | 82.19 % | 0 % | 0 % |
| 2007 | 82.19 % | 0 % | 0 % |
| 2008 | 82.19 % | 0 % | 0 % |
| 2009 | 82.19 % | -106.27 % | -106.15 % |
| 2010 | 82.19 % | 0 % | 0 % |
| 2011 | 82.19 % | 0 % | 0 % |
| 2012 | 82.19 % | 0 % | 0 % |
| 2013 | 82.19 % | 0 % | 0 % |
| 2014 | 82.19 % | 0 % | 0 % |
| 2015 | 82.19 % | -3,959.43 % | -3,953.77 % |
| 2016 | 82.19 % | -12,640.32 % | -12,611.29 % |
| 2017 | 82.19 % | 0 % | 0 % |
| 2018 | 83.6 % | -1,928.93 % | -1,982.8 % |
| 2019 | 89.63 % | -476.36 % | -505.47 % |
| 2020 | 76.6 % | -107.24 % | -117.95 % |
| 2021 | 82.19 % | 28.83 % | 25.96 % |
| 2022e | 82.19 % | 4.23 % | 1.94 % |
| 2023e | 82.19 % | 13.69 % | 9.19 % |
| 2024e | 82.19 % | 23.57 % | 15.83 % |
| 2025e | 82.19 % | 51.01 % | 34.42 % |
| 2026e | 82.19 % | 82.78 % | 80.08 % |
La Jolla Pharmaceutical Aktienanalyse
What does La Jolla Pharmaceutical do?
La Jolla Pharmaceutical Co is a biopharmaceutical company specializing in the development and marketing of medicines for the treatment of rare and severe diseases. It was founded in 1989 in San Diego, California, by physician and scientist Ivor Royston. The company's business model is focused on researching, developing, and marketing drugs for patients with rare or severe diseases. The company prioritizes the needs and requirements of patients and aims to tailor each medication to maximize effectiveness. La Jolla's main focus is on researching medications for severe and rare diseases such as sepsis, acute kidney failure, and lung inflammation. These medications are intended to help patients who have limited or no treatment options. The company's portfolio includes various drugs, with antibodies being an important component for the treatment of inflammation and autoimmune diseases. Notably, Giapreza is one of the company's well-known medications approved by the FDA in December 2017, designed to treat adult patients with severe or most severe septic shock by increasing blood pressure. LJPC-401 is another significant medication developed by La Jolla Pharmaceutical Co, intended for the treatment of lupus nephritis, an autoimmune-related kidney inflammation that affects about 50% of systemic lupus erythematosus (SLE) patients. The company is also working on the development of a medication for migraine treatment, aiming to reduce the severity and frequency of migraine attacks. Overall, La Jolla Pharmaceutical Co has made significant progress in expanding its research activities and is committed to developing innovative medications to improve the lives of patients with rare and severe diseases. The company's focus on patient needs has proven to be a strategic advantage, positioning it competitively for the future. La Jolla Pharmaceutical ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing La Jolla Pharmaceutical's EBIT
La Jolla Pharmaceutical's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of La Jolla Pharmaceutical's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
La Jolla Pharmaceutical's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in La Jolla Pharmaceutical’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about La Jolla Pharmaceutical stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company La Jolla Pharmaceutical.
How has the EBIT of La Jolla Pharmaceutical developed in recent years?
The EBIT of La Jolla Pharmaceutical has increased by 104.379% increased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company La Jolla Pharmaceutical?
The EBIT of La Jolla Pharmaceutical is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does La Jolla Pharmaceutical pay?
Over the past 12 months, La Jolla Pharmaceutical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, La Jolla Pharmaceutical is expected to pay a dividend of 0 USD.
What is the dividend yield of La Jolla Pharmaceutical?
The current dividend yield of La Jolla Pharmaceutical is .
When does La Jolla Pharmaceutical pay dividends?
La Jolla Pharmaceutical pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of La Jolla Pharmaceutical?
La Jolla Pharmaceutical paid dividends every year for the past 0 years.
What is the dividend of La Jolla Pharmaceutical?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is La Jolla Pharmaceutical located?
La Jolla Pharmaceutical is assigned to the 'Health' sector.
Wann musste ich die Aktien von La Jolla Pharmaceutical kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of La Jolla Pharmaceutical from 9/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/10/2024.
When did La Jolla Pharmaceutical pay the last dividend?
The last dividend was paid out on 9/10/2024.
What was the dividend of La Jolla Pharmaceutical in the year 2023?
In the year 2023, La Jolla Pharmaceutical distributed 0 USD as dividends.
In which currency does La Jolla Pharmaceutical pay out the dividend?
The dividends of La Jolla Pharmaceutical are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The La Jolla Pharmaceutical stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von La Jolla Pharmaceutical
Our stock analysis for La Jolla Pharmaceutical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of La Jolla Pharmaceutical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- La Jolla Pharmaceutical Revenue
- La Jolla Pharmaceutical Net Income
- La Jolla Pharmaceutical P/E
- La Jolla Pharmaceutical P/S
- La Jolla Pharmaceutical EBIT
- La Jolla Pharmaceutical Dividend
- La Jolla Pharmaceutical Stocks
- La Jolla Pharmaceutical Market capitalization
- La Jolla Pharmaceutical Debt
- La Jolla Pharmaceutical Liabilities
- La Jolla Pharmaceutical Equity
- La Jolla Pharmaceutical AAQS
- La Jolla Pharmaceutical Employees
- La Jolla Pharmaceutical ROE
- La Jolla Pharmaceutical ROA
- La Jolla Pharmaceutical ROCE
